Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Shiga University of Medical Science Wants to Correct Diovan Paper, Sent Data Found During Diovan Probe to US Journal
December 27, 2013
- Chuikyo Reps Slam Inter-Ministerial Deal to Scrap Insurance Coverage for Gargles
December 27, 2013
- Chuikyo Approves 60% Upper Limit for Evaluating Generic Drug Use at DPC Hospitals
December 27, 2013
- Trial of Cost-Effective Assessment Should Be Postponed Until FY2016 at Earliest: Expert Subcommittee
December 27, 2013
- MHLW Pitches Dispensing Fee Cuts for Hospitals, Pharmacies with Low Price Settlement Rates
December 26, 2013
- Active Recommendation for HPV Vaccines Remains Suspended
December 26, 2013
- Gist of FY2014 NHI Price Revision
December 26, 2013
- Health Ministry to Request Hospitals to Inspect Clinical Studies Initiated between FY2000 and 2008
December 26, 2013
- Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
- Regulatory Reform Council Gives Directions for Expansion of Special Scheme for Mixed Healthcare, Yet No Concrete Plan
December 26, 2013
- Health Ministry Committee Decides Details of Drug Safety Evaluation after Rx-to-OTC Switches
December 26, 2013
- FY2014 Budget: 95.4 Billion Yen for Japan NIH, Development of Novel Drugs
December 25, 2013
- Government to Allocate 8,696 Million Yen in FY2014 Budget for Faster Drug Review, Pharma Business Revitalization
December 25, 2013
- FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
- MHLW Will Level Charges against Novartis, If Necessary: Minister
December 24, 2013
- Premium for Innovativeness or Usefulness (I) Set as Prerequisite for 10% “Precursor Premium”
December 20, 2013
- Generic Share Fails to Meet FY2012 Target but Reaches 47% in New Calculation Method
December 20, 2013
- Chuikyo’s DPC Subcommittee Continues to Support Original Proposal on Generic Drug Index; Will Report Accordingly at Upcoming General Meeting
December 20, 2013
- PhRMA Japan Head, Other Observers Invited for Comments for First Time at Health Ministry Vaccination Panel
December 20, 2013
- Vaccine Dose Intervals to Become More Flexible Starting Next April
December 20, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…